Sarcopenia is a poor prognostic factor of castration-resistant prostate cancer treated with docetaxel therapy
Background: Sarcopenia is a geriatric syndrome that is characterized by the gradual muscle loss and frailty in the elderly. Meanwhile, the prevalence of prostate cancer is on the rise worldwide. Mainstay treatments for metastatic prostate cancer are androgen-deprivation therapy and taxane-based chem...
Main Authors: | Ayako Ohtaka, Hiroaki Aoki, Masayoshi Nagata, Mayuko Kanayama, Fumitaka Shimizu, Hisamitsu Ide, Akira Tsujimura, Shigeo Horie |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-03-01
|
Series: | Prostate International |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2287888217301514 |
Similar Items
-
The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide
by: So Nakamura, et al.
Published: (2024-02-01) -
Significant association between urethral length measured by magnetic resonance imaging and urinary continence recovery after robot-assisted radical prostatectomy
by: Kosuke Kitamura, et al.
Published: (2019-06-01) -
Editorial: Circulating biomarkers in prostate cancer
by: Masayoshi Nagata, et al.
Published: (2024-02-01) -
Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01) -
Efficacy of cabazitaxel and androgen splicing variant-7 status in circulating tumor cells in Asian patients with metastatic castration-resistant prostate cancer
by: Takeshi Ashizawa, et al.
Published: (2022-10-01)